Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: Occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial  by Miller, D. Craig et al.
A
C
D
ACQUIRED CARDIOVASCULAR DISEASETranscatheter (TAVR) versus surgical (AVR) aortic valve
replacement: Occurrence, hazard, risk factors, and consequences of
neurologic events in the PARTNER trialD. Craig Miller, MD,a Eugene H. Blackstone, MD,b Michael J. Mack, MD,c Lars G. Svensson, MD, PhD,b
Susheel K. Kodali, MD,d Samir Kapadia, MD,b Jeevanantham Rajeswaran, MSc,b
William N. Anderson, PhD,e Jeffrey W. Moses, MD,d E. Murat Tuzcu, MD,b John G. Webb, MD,f
Martin B. Leon, MD,d and Craig R. Smith, MD,d on behalf of The PARTNER Trial Investigators and
Patients, The PARTNER Stroke Substudy Writing Group and Executive CommitteeFrom St
dation
versit
Lifesc
Vanco
Clinical
Disclosu
Read at
gery,
Receive
public
Address
racic
of Me
0022-52
Copyrig
doi:10.1
832Background: All neurologic events in the PARTNER randomized trial comparing transcatheter aortic valve re-
placement (TAVR) with surgical aortic valve replacement (AVR) were analyzed.
Methods: High-risk patients with aortic stenosis were stratified into transfemoral (TF, n ¼ 461) or transapical
(TA, n ¼ 196) strata based on their arterial anatomy and randomized: 657 received treatment assigned (‘‘as
treated’’), 313 underwent AVR, and 344 TAVR. Neurologic events were prospectively adjudicated by an inde-
pendent Clinical Events Committee. Multivariable, multiphase hazard analysis elucidated factors associated
with increased likelihood of neurologic events.
Results: Forty-nine neurologic events (15 transient ischemic attacks, 34 strokes) occurred in 47 patients (TAVR,
n¼ 31;AVR, n¼ 16). An early peaking high hazard phase occurredwithin the first week,which declined to a con-
stant late hazard phase out to 2 years. The risk in the early phasewas higher after TAVR thanAVR, and in theTAVR
arm in patients with a smaller aortic valve area index. In the late risk phase, the likelihood of neurologic event was
linked to patient-related factors in both arms (‘‘non-TF candidate,’’ history of recent stroke or transient ischemic
attack, and advanced functional disability), but not by treatment (TAVR vsAVR) or any intraprocedural variables.
The likelihood of sustaining a neurologic event was lowest in theAVR subgroup in the TF stratumduring all avail-
able follow-up.
Conclusions: After either treatment, there were 2 distinct hazard phases for neurologic events that were driven
by different risk factors. Neurologic complications occurred more frequently after TAVR than AVR early,
but thereafter the risk was influenced by patient- and disease-related factors. (J Thorac Cardiovasc Surg
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The Journal of Thoracic and Cardiovascular SurgerySupplemental material is available online.In the randomized PARTNER (Placement of AoRTic
TraNscathetER Valves) trial1 (ClinicalTrials.gov identifier
NCT00530894), neurologic events occurred more fre-
quently after transcatheter aortic valve replacement
(TAVR) than after surgical aortic valve replacement
(AVR) at 30 days and 1 year in high surgical risk patients
with severe aortic stenosis (AS).2 These events were associ-
ated with substantial mortality1,2 and have become a focal
point in evaluating the safety of TAVR.
The aim of this study was to investigate comprehensively
the nature of all neurologic events occurring after TAVR or
AVR, the temporal pattern of their occurrence and associa-
tion with risk factors, the likelihood of such an event occur-
ring within the lifetime of patients, and the mortality
consequences of these events. Such knowledge will be use-
ful in identifying the cause of these events, devising ways toc April 2012
Abbreviations and Acronyms
AF ¼ atrial fibrillation
AS ¼ aortic stenosis
AT ¼ as treated
AVAI ¼ aortic valve area index
AVR ¼ aortic valve replacement
BAV ¼ balloon aortic valvuloplasty
CABG ¼ coronary artery bypass grafting
CEC ¼ Clinical Event Committee
ITT ¼ intent to treat
PARTNER ¼ Placement of AoRTic
TraNscathetER Valves (trial)
STS ¼ The Society of Thoracic Surgeons
TA ¼ transapical
TAVR ¼ transcatheter aortic valve
replacement
TF ¼ transfemoral
TIA ¼ transient ischemic attack
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Dprevent them, and providing decision support and realistic
expectations for patients.
PATIENTS AND METHODS
ThePARTNERtrial design, inclusion andexclusion criteria, andother de-
tails have been previously reported1,2 and are summarized in Appendix E1.
Patients
Among 699 intent to treat patients (ITT) with severe AS who were high
risk (10%-15% Society of Thoracic Surgeons [STS] mortality score3,4)
for open AVR,2 657 who received treatment assigned (‘‘as treated,’’ or AT)
were stratified into either the transfemoral (TF, n¼ 461) or transapical (TA,
n ¼ 196) stratum (see CONSORT diagram, Figure E1). Patients were clas-
sified as either TF or TA based on a ‘‘TF first’’ philosophy according to
whether their arterial anatomy was suitable (>7-mm lumen diameter) for
the 22Fr or 24Fr sheaths required for insertion of TF 23-mm and 26-mm
SAPIEN valves (Edwards Lifesciences, Irvine, Calif). They were then ran-
domized within each stratum to undergo either TAVR (n ¼ 344) or AVR
(n¼ 313, Figure E1), thereby creating separate parallel control (AVR) sub-
groups for direct comparison with TAVR patients within each stratum.
Among the 461 AT patients in the TF stratum, 240 were randomized to
TAVR and 221 to AVR. Beginning April 6, 2008, about 1 year after the
TF limb of the trial started, if a patient anatomically was not a suitable can-
didate for TF-TAVR, TA-TAVR was performed through a small intercostal
incision over the left ventricular apex. There were 196 AT patients in the
TA stratum: 104 randomized to TAVR, and 92 to AVR.
Pertinent characteristics of the 657 PARTNER high-risk AT patients ac-
cording to assigned stratum (TA or TF) are summarized in Table E1. They
had critical AS (mean aortic gradient ¼ 41  13 vs 44  15 mm Hg [1
SD], aortic valve area¼ 0.7 0.2 vs 0.6 0.2 cm2), were elderly (average
age 83  6 vs 84  7 years, respectively), very high risk (STS
score ¼ 11.9%  3.6% vs 11.7%  3.3%, Log EuroSCORE ¼ 30% 
16% vs 29%  16%), highly symptomatic (New York Heart Association
class III-IV in 94% vs 95%), and had many serious medical comorbidities.
Significantly more patients with previous carotid endarterectomy or stent-
ing, peripheral arterial bypass grafting/stenting/balloon dilatation, coro-
nary artery bypass grafting (CABG), cerebrovascular disease, andThe Journal of Thoracic and Caperipheral arterial vascular disease were in the TA stratum compared
with the TF stratum, reflecting more generalized arteriosclerotic burden
(Figure E2). This was confirmed in a parsimonious multivariable logistic
regression model (see Appendix E1 methods and Table E2).
The pooled patient characteristicswere similar according towhether they
were randomized to TAVR or AVR (ie, both TF and TA strata combined,
Table E3). Table E4 lists important clinical features for all 4 subgroups.
Patient Management
Patients received heparin during the TAVR procedure, and dual antipla-
telet therapy (aspirin and clopidogrel) was recommended for 6 months
postoperatively. Warfarin anticoagulation and the duration of antiplatelet
therapy were left to the discretion of local physicians.
End Points
End points included were all neurologic events and all-cause mortality
for all available follow-up. All adverse clinical events were independently
reviewed in a blinded, prospective manner by the Clinical Event Commit-
tee (CEC), including neurologic complications. See Appendix E1 for com-
plete details concerning neurologic assessment. Our ability to determine
precisely the severity and permanence of neurologic damage was limited
in the PARTNER-I trial. All neurologic events were combined to provide
sufficient power for a hazard function model and to analyze the clinical im-
portance of all types of neurologic complications.5,6
Data Analysis
See Appendix E1 for detailed statistical methods. In brief, the instanta-
neous temporal pattern of risk of neurologic events was characterized by
multiphase hazard function methodology that distinguished early from
later phases of risk. Risk factors for neurologic events were identified for
each hazard phase, including detailed search for interaction terms. Likeli-
hood of a neurologic event occurring during a patient’s lifetime was esti-
mated by competing risks analysis, with death as the competing risk.
Mortality consequences of a neurologic event were estimated by analysis
of death after such an event compared with expected deaths had a neuro-
logic event not occurred.RESULTS
Nature of Neurologic Events
Forty-nine neurologic events (15 transient ischemic at-
tacks [TIAs], 34 strokes) occurred in 47 patients (TAVR:
31 patients, 31 events; AVR: 16 patients, 18 events). Timing
and type of neurologic events are shown in Table 1. Fifty-
one percent (24/49) were procedure related (<10 days)
and 38% (18/49) occurred within the first 2 days. Eighteen
(58%) of 31 TAVR patients who sustained neurologic
events had a major stroke, similar to 69% (11/16) of the
AVR patients. At 10 days, the major stroke rate was 3.4%
(12/344) in the TAVR and 1.9% (6/313) in the AVR treat-
ment arms. The neurologic event was a TIA in 26% (12/
47) of patients (29% of the total 49 events). Etiology was
judged to be ischemic in 72%, ischemic evolving to hemor-
rhagic in 4%, unknown in 24%, and hemorrhagic in none.
One AVR patient who sustained a major stroke at 7 days had
a second event (TIA) at 9 days; another AVR patient who
had a TIA between 1month and 1 year experienced a second
TIA 411 days postoperatively. Twenty (43%) of the 47 pa-
tients with a neurologic event ultimately died, compared
with 29% (174/610) of those without a neurologic event.rdiovascular Surgery c Volume 143, Number 4 833
TABLE 1. Timing and type of 49 neurologic events in 47 patients
AT time 0-2 d 3-5 d 6-10 d 11-30 d 31-364 d 1-2 y 2-3 y Total
TAVR
TIA 2 0 0 1 4 1 0 8
Minor CVA 3 0 0 0 0 2 0 5
Major CVA 7 2 3 0 5 1 0 18
Subtotal 12 2 3 1 9 4 0 31
AVR
TIA 0 0 0 (1*) 0 3 1 (1*) 0 4 (2*)
Minor CVA 1 0 0 0 0 0 0 1
Major CVA 5 0 1 1 1 2 1 11
Subtotal 6 0 1 (1*) 1 4 3 (1*) 1 16 (2*)
Total 47 (49*)
AT time, ‘‘As treated’’ time elapsed since start of the procedure; TIA, transient ischemic attack; CVA, cerebrovascular accident; TAVR, transcatheter aortic valve replacement; AVR,
aortic valve replacement. *Second event.
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The instantaneous risk of neurologic events after TAVR
or AVR demonstrated an early, peaking high hazard phase
in the first postoperative week followed by a constant lower
hazard phase throughout the duration of follow-up
(Figure 1, A). This temporal pattern is similar to that seen
for stroke after CABG, where the peak hazard occurs about
postoperative day 2.7 The shape of the hazard function sug-
gested that different risk factors were present early after ei-
ther procedure compared with later (nonproportional
hazards), likely representing different mechanisms; Table
2 summarizes the early and late independent predictors of
neurologic events. In the early high hazard phase, TAVR
(Figure 1, A) and smaller aortic valve area index (AVAI,
cm2/m2) in the TAVR arm (Figure 1, B) were associated
with a significantly increased risk of a neurologic event;
in the AVR treatment arm the effect of smaller AVAI was
not observed. History of cerebrovascular disease was possi-
bly associated with higher risk. The early high hazard phase
for patients assigned to the TF stratum (Figure 1, C) under-
scored the higher risk of neurologic events in the TF-TAVR
arm than in the AVR subgroup. For patients in the TA stra-
tum, early hazard after TA-TAVR in the first week (Figure 1,
D) was slightly lower than after AVR but more prolonged
out to about 2 weeks, then slowly rose to 24 months in
the late hazard phase (Figure 1, E).
These hazard functions translated into an early separa-
tion of neurologic event curves during the first week be-
tween the pooled TAVR and AVR treatment arms
(Figure 2, A), which thereafter slowly rose in parallel. At
2 years, the point estimate of neurologic events was
6.7% in the pooled AVR arm and 11% in the pooled
TAVR arm. For patients in the TF stratum, the point esti-
mate of neurologic events was 2.4% after AVR versus
6% after TF-TAVR at 1 year and 3.4% and 7.4%, respec-
tively, at 2 years (Figure 2, B). For patients in the TA stra-
tum, Figure 2, C, illustrates that occurrence of stroke or
TIA was similar in both treatment arms but higher than834 The Journal of Thoracic and Cardiovascular Surgthat observed in the TF stratum: 10% after AVR versus
12% after TA-TAVR at 1 year.
During the late hazard phase, treatment armwas not a sig-
nificant risk factor for neurologic events. Rather, patient-
related and disease-related characteristics were incremental
risk factors for neurologic events (see Table 2), including
advanced functional impairment (New York Heart Associa-
tion functional class) (Figure 3, A) and history of stroke
within 6 to 12months. The point estimate of new neurologic
event in those with a previous stroke or TIA was 23% at 2
years compared with 8.9% for those without a neurologic
event (Figure 3, B). (NB: Stroke or TIA within 6 months
was a PARTNER exclusion criterion.) Patients with a his-
tory of percutaneous coronary intervention or chronic ob-
structive pulmonary disease had lower late risk. The
strongest and most statistically significant late risk factor
was being judged to be a ‘‘non-TF candidate,’’ viz, assigned
to the TA stratum. Importantly, the strength of this ‘‘non-TF
candidate’’ factor in the TAVR treatment arm (12% of TA-
TAVR patients had sustained a neurologic event by 1 year vs
6% in the TF-TAVR subset, Figure 3, C) was just as power-
ful in the AVR arm (10% of AVR patients in the TA stratum
had sustained a neurologic event by 1 year vs 2.4% of AVR
patients in the TF stratum, Figure 3, D). Hence, the adverse
effect of TA stratum affected both treatment arms similarly.
Presence of arteriosclerotic peripheral arterial disease
was not identified as a risk factor. Two variables represent-
ing preprocedural cardiac arrhythmias were assessed (one
being clinical history of arrhythmias that was loosely con-
sidered to represent atrial fibrillation [AF], and the other
an adjudicated AF variable determined on a single electro-
cardiogram by the ECG Core Lab). Both were examined in
this analysis, but neither was identified to be a risk factor for
neurologic events in either hazard phase.
Only 29 major strokes occurred, precluding robust statis-
tical analysis. The confidence limits for major stroke in the
pooled (TA and TF strata combined) TAVR and AVR pa-
tients overlapped (Figure E3, A): point estimates at 2 yearsery c April 2012
FIGURE 1. Risk of neurologic events after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (AVR). A, Instantaneous
hazard (calculated as percent/month) of a neurologic event after procedure for pooled TAVR and AVR arms. Solid lines represent parametric estimates and
are enclosed within asymmetric confidence bands equivalent to  1 standard error. Red curve is for TAVR and blue curve for AVR. B, Probability of neu-
rologic event at 3 months within the TAVR treatment arm as a function of native aortic valve area index (AVAI) and assignment to the transfemoral (TF) or
transapical (TA) stratum. This depiction is a nomogram of the equation represented in Table 2 with values for all variables held constant except for whether or
not the patient was a suitable candidate for TF-TAVR. The nomogram was solved with the following values for variables in the model: TAVR ¼ yes, ce-
rebrovascular disease ¼ no, New York Heart Association ¼ IV, stroke within 6 to 12 months ¼ no, history of percutaneous coronary intervention ¼ no,
chronic obstructive pulmonary disease ¼ no. Solid lines represent parametric estimates and are enclosed within asymmetric confidence bands equivalent
to  1 standard error. C, Hazard function for neurologic events after either TAVR or AVR among patients assigned to the transfemoral (TF) stratum. De-
piction is as in Figure 1, A. D, Hazard function for neurologic events after either TAVR or AVR among patients assigned to the transapical (TA) stratum.
Depiction is as in Figure 1, A. E, Instantaneous hazard to 24 months for neurologic events after either TAVR or AVR among patients assigned to the trans-
apical (TA) stratum. Depiction is as in Figure 1, A.
Miller et al Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery c Volume 143, Number 4 835
A
C
D
TABLE 2. Incremental risk factors for neurologic events after
procedure (including factors specific to procedure performed)
Risk factor Coefficient ± SD P R (%)
Early hazard phase
TAVR* 2.21  0.68 .001 59
Cerebrovascular disease 0.76  0.45 .09 44
(Smaller) indexed native
aortic valve areay in
TAVR group
11.8  5.1 .02 57
Constant hazard phase
TAVR 0.40  0.43 .4 22
(Higher) NYHA 0.95  0.40 .02 75
Stroke within 6-12 mo 1.93  0.64 .002 60
Non–TF-TAVR candidate 2.3  0.45 <.0001 96
History of PCI (less risk) 1.60  0.63 .01 77
COPD (less risk) 1.06  0.47 .03 79
R (%), or bagging reliability, is interpreted as the probability ofP<.07 and represents
the proportion of 500 bootstrap analyses in which this variable was retained with
P < .07. SD, Standard deviation; TAVR, transcatheter aortic valve replacement;
NYHA, New York Heart Association; TF, transfemoral; PCI, percutaneous coronary
intervention; COPD, chronic obstructive pulmonary disease. *Once interactions are
considered, the variable TAVR becomes an offset to the intercept term in the model.
y(Valve area/body surface area)2 squared transformation.
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AVR treatment arm. There was, however, both an early
(Figure E3, B) and a continuing late risk of major stroke
(Figure E3, C). After AVR the early phase estimates for ma-
jor stroke and all neurologic events were similar. Although
the area under the major stroke early hazard phase curve for
TAVR was insignificantly less than after AVR (P ¼ .3), the
duration of the early phase extended to about 1 week com-
pared with the initial 1 to 2 days after AVR (Figure E3, B).Likelihood of Neurologic Event-Free Survival
The likelihood of being alive and free of a neurologic
event is shown according to treatment arm (TAVR vs
AVR) and TF or TA stratum in Figure E4, A to D, superim-
posed with the likelihood of experiencing a neurologic
event or of dying before such an event occurs. Values for
these competing risks of neurologic event and death from
the 4 subsets are stacked in a single graph (Figure 4) with
an expanded vertical scale to illustrate the ‘‘mortality-ad-
justed’’ likelihood of being alive and not having sustained
a neurologic event. Likelihood at 2 years was lowest
(2.6%, most favorable outcome) for the AVR patients in
the TF stratum versus 6.9% for the TF-TAVR patients.
For either TAVR or AVR patients in the TA stratum, the
likelihood was substantially higher, but similar between
treatment arms; the point estimate at 1 year was 9.1% for
AVR patients and 11% for TAVR patients. Note that the
curves representing the TA stratum patients (treated either
way) rose steeply late postoperatively compared with the
corresponding flat curves in the TF stratum, consistent
with the ‘‘non-TF candidate’’ variable being the dominant
predictor of stroke or TIA in the late hazard phase (Table 2).836 The Journal of Thoracic and Cardiovascular SurgMortality Consequences
Observed mortality after a neurologic event was higher
than that expected had a neurologic event not occurred
(based on the competing risk estimates for death before
a neurologic event). Thus, as explained in Appendix E1,
conditional survival, which starts at 100% at the time of
a neurologic event, was computed on the basis of the sur-
vival experience of all patients, thereby allowing meaning-
ful comparison of prognoses after an event. This is shown in
Figure E5, A to F, for the pooled AVR, TF-TAVR, and
TA-TAVR groups; for clarity, estimated life expectancy
was expressed as the hazard ratio of observed to expected
mortality (Figure 5). For the pooled AVR patients, the haz-
ard ratio was high early after the neurologic event for about
6 weeks; thereafter, it returned to 1.0 (expected mortality
risk) out to 1 year (see Figure 5, A). For TAVR-TF patients,
the high risk of mortality after an event remained elevated
over the first year, only slowly approaching 1.0 (Figure 5,
B). For TAVR-TA patients, the elevated risk of death after
a neurologic event remained high throughout the first year
(Figure 5, C).DISCUSSION
Although surgical AVR remains the gold standard, at
least one third of symptomatic patients with ASmay not un-
dergo AVR owing to comorbidities such as advanced age
and frailty, life-limiting other medical diseases, or patient
choice.8 TAVR outside the United States is an alternative
to AVR and in 2010 accounted for 24% (3629/15,318) of
all AVRs performed in 79 centers in Germany (1450 via
a transvascular approach and 2179 via the TA approach).9
Observational studies have demonstrated the utility of
TAVR using either the balloon-expandable SAPIEN bovine
pericardial or the self-expanding CoreValve (Medtronic,
Inc, Minneapolis, Minn) porcine pericardial device in
high-risk and inoperable patients10,11; while procedural
success has become the norm, complications (including
stroke and vascular complications) have been noteworthy.
The risk of stroke after TAVR has been reported in
the 2.4% to 9.1% range for TF-TAVR and 1.5% to 6.7%
for TA-TAVR.10,11 This variability may be explained
by differences in study design (retrospective vs
prospective5,6), sample size, methodology used,5 patient
substrate and site-specific factors, and voluntary self-report-
ing.5 As shown in many different stroke studies, lack of in-
dependent adjudication leads to underreporting, making it
impossible to compare devices or approaches.
The PARTNER trial was the first prospective randomized
investigation comparing TAVR and AVR in inoperable and
high-risk operable patients with severe AS.1,2 Inoperable
(cohort B) patients were randomized between TAVR and
optimal medical therapy, which demonstrated an absolute
20% reduction in mortality at 1 year after TAVR, alongery c April 2012
FIGURE 2. Occurrence of neurologic events after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (AVR). Each symbol
represents an event; vertical bars are confidence limits equivalent to  1 standard error, and solid lines represent parametric estimates enclosed within
dashed confidence bands indicating  1 standard error. Number of patients remaining at risk is denoted below the horizontal axis at 6-month intervals.
Red curve and open squares depict the TAVR treatment arm, and blue curve and open circles the surgical AVR arm. Numbers within the plot are point es-
timates at 12 and 24 months. A, Occurrence of neurologic events according to treatment arm. B, Occurrence of neurologic events among patients assigned to
the transfemoral (TF) stratum. C, Occurrence of neurologic events among patients assigned to the transapical (TA) stratum.
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curred, however, including a 6.7% incidence of neurologic
events at 30 days with a 5% major stroke rate.1 This higher
risk of neurologic complications compared with medical
therapy is acceptable in these inoperable patients given
the marked symptomatic and survival benefit.
Stroke also is a widely recognized complication after sur-
gical AVR, especially in elderly patients,3 but unfortunately
in the literature stroke is not strictly defined, neurologic
events are not independently adjudicated, and the majority
of the reports are from voluntary databases or single-center
experiences.12,13 Prospective, more rigorous reports are
rare.5 Voluntary self-reported databases, including the STS
database,3,4 underestimate the risk of stroke, use varying
subjective definitions, and lack independent adjudication of
adverse events or universal auditing. Stroke rates in
elderly, high-risk patients undergoing surgical AVR gener-
ally ranged from 2% to 4%3-5; however, in 2 recent single-The Journal of Thoracic and Cacenter reports of high-risk patients with previous CABG
undergoing surgical AVR, the stroke rates were 11% for
those older than 75 years12 and 8% in those over 80.13
High-risk, operable patients (PARTNER cohort A) were
randomized between TAVR and AVR (ITT, n¼ 699).2 Neu-
rologic events were more frequent in TAVR patients. The
incidence of neurologic events in the TAVR arm was twice
as high as in the AVR arm (5.5% vs 2.4% at 30 days
[P ¼ .04], and 8.3% vs 4.3% at 1 year [P ¼ .04], respec-
tively, ITT cohorts), although the rate of major stroke was
not significantly different (3.8% vs 2.1% [P ¼ .20] at 30
days and 5.1% vs 2.4% [P ¼ .07] at 1 year, respectively).2
For the PARTNER high-risk AT patients, the rate of neuro-
logic events in the TF stratum was 3-fold higher after TAVR
(n ¼ 240) than after AVR (n ¼ 221): 4.6% vs1.4% at 30
days (P¼ .04) and 6.1% vs 1.9% at 1 year (P¼ .03), (Sup-
plementary Appendix Table 9, see Smith and associates2),
which attracted scrutiny.14 This low 30-day neurologicrdiovascular Surgery c Volume 143, Number 4 837
FIGURE 3. Occurrence of neurologic events for all patients (transcatheter aortic valve replacement [TAVR] and surgical aortic valve replacement [AVR]
treatment arms combined, except as noted) stratified by risk factors (see Table 2). Vertical bars are confidence limits equivalent to 1 standard error. Num-
ber of patients at risk is denoted below the horizontal axis at 6-month intervals.Numberswithin the plot are point estimates at 12 and 24months. A, Actuarial
estimates of neurologic events stratified by New York Heart Association (NYHA) functional class. B, Actuarial estimates of neurologic events stratified by
presence or absence of stroke or transient ischemic attack in last 6 to 12 months. C, Occurrence of neurologic events after TAVR, stratified by whether the
patient was assigned to transfemoral (TF) or transapical (TA) stratum (this stratum designator was applied to patients in both treatment arms [TAVR or
AVR]). Depiction is as in Figure 2, A, except that the brown curve is for the TF candidates who underwent TAVR and the green curve for TA-TAVR patients.
D, Occurrence of neurologic events after AVR stratified bywhether the patient was assigned to the transfemoral (TF) or transapical (TA) stratum (this stratum
designator applied to patients in both treatment arms [TAVR or AVR]). Depiction is as in Figure 3, C.
Acquired Cardiovascular Disease Miller et al
A
C
Devent rate of 1.4% after AVR is striking given how old and
sick the PARTNER cohort A patients were, rivaling the
1.3% stroke rate in 2689 younger AVR patients.15 In the
TA stratum, the neurologic event rates were higher in
both the TAVR and AVR treatment arms (7.9% vs 5.5%
at 30 days, P ¼ .5; 14.1% vs 9.7% at 1 year, P ¼ .37, re-
spectively) and of similar magnitude (Supplementary Ap-
pendix Table 11, see Smith and associates2). Similar to
the ITTanalyses, the incidence of major stroke in the AT pa-
tients was similar between the TAVR and AVR arms in both
strata.2 If a neurologic event occurred, however, the ensuing
1-year mortality rate was higher after TAVR than after
AVR2; however, the composite end point of death and major
strokewas not significantly different between the TAVR and
AVR patients at 1 year (26.5% vs 28%, respectively
[P ¼ .7]).838 The Journal of Thoracic and Cardiovascular SurgIn contrast to the earlier PARTNER trial results, which
were truncated at 1 year,1,2 this analysis looked at all
neurologic events regardless of time and revealed several
novel findings: (1) In both treatment arms, there was an
early peaking high hazard phase of neurologic events
within the first week, which was followed thereafter by
a late constant hazard phase. (2) Neurologic events of all
types continued unabated, at a lower level, throughout
follow-up. (3) The temporal pattern of neurologic events
was generally similar after AVR and TAVR, but the early
risk of neurologic events was substantially higher after
TAVR, particularly in the TF stratum (Figure 1, A). (4)
Within the TAVR treatment arm, the early risk of neurologic
event was elevated in those with a smaller AVAI (Figure 1,
B), most likely owing to the tighter valves having more cal-
cification that potentially could embolize during TAVR. (5)ery c April 2012
FIGURE 4. Likelihood of neurologic event when the competing risk of death is taken into consideration in each of the 4 treatment subgroups. Depicted in
light blue is the curve for the likelihood of a neurologic event after aortic valve replacement (AVR) in the TF stratum, the salmon-colored curve is that for
AVR patients assigned to the TA stratum, the brown curve is for the transfemoral transcatheter aortic valve replacement (TF-TAVR) patients in the TF stra-
tum, and the green curve is for the TA-TAVR patients in the transapical stratum. These are the 4 lower curves labeled ‘‘Neurologic event’’ in each of the
individual competing risks graphs (Figure E4, A-D), but on an expanded vertical scale. Within each subgroup, the fractions alive without a neurologic event,
dead before a neurologic event, and sustaining a neurologic event are shown individually in Figure E4, A-D. Number of patients at risk are denoted below the
horizontal axis at 6-month intervals.
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‘‘non–TF-TAVR candidate’’ (more severe, generalized ath-
erosclerotic burden), history of antecedent stroke or TIA,
and more advanced functional disability, with similar ad-
verse impacts across both the TAVR and AVR treatment
arms (Figure 3, C to D). (6) Preoperative rhythm (or surro-
gates for AF) could not be linked to neurologic events. (7)
Using competing hazards (death or sustaining a neurologic
event) analysis, the AVR subset in the TF stratum had the
most favorable outcome at 2 years, that is, being alive and
free from a neurologic event, whereas those in the TA-
TAVR subgroup had the highest rate of adverse events
(Figure 4). (8) Neurologic events after TAVR or AVR car-
ried different mortality consequences (Figure 5).
The ‘‘non-TF candidate’’ risk factor represents a compos-
ite marker that coalesces patient and disease information.
To explore this further, we repeated the bagging analysis
with the preoperative ‘‘non-TF candidate’’ variable sup-
pressed: the variables identified by bagging remained the
same except for previous CABG (positive coefficient) en-
tering the late hazard phase. Thus, the higher neurologic
event rates in the TA stratum compared with the TF stratum
were due to patient-related and/or disease-related factors,
rather than some intrinsic feature of the TA-TAVR approach
per se. There is no evidence available today, however, indi-
cating that the risk of stroke during TF-TAVR will be lower
using the next generation systems. Preliminary observationsThe Journal of Thoracic and Cafrom the Prevail EU Registry in Europe using the Edwards
SAPIENXT valve and 18Fr and 19Fr TF NovaFlex delivery
systems (Edwards Lifesciences) showed no drop in the in-
cidence of stroke compared with the historical rates using
the original SAPIEN valve.
Although TAVR is associated with higher early neuro-
logic event rates, the responsible mechanism(s) remain un-
clear. Possible causes of brain injury include hypotension or
hypertension, hemorrhagic events possibly related to anti-
coagulation, and emboli.16-18 The most likely cause of the
early phase strokes and TIAs is gaseous or particulate
cerebral embolization, probably owing to manipulation of
guide wires and catheters across tightly stenotic aortic
valves and the aortic arch or the preparatory balloon
aortic valvuloplasty (BAV).18 Expansion of the TAVR bio-
prosthetic frame resulting in traumatic distortion of native
valve elements and creating niduses of stagnant blood
flow in the small remaining space within the aortic root
may be a source of particulate debris or thromboem-
boli.16,18 Transcranial Doppler monitoring of middle
cerebral artery flow to detect microembolic signals during
TAVR showed showers during the preparatory BAV and
valve delivery phases of TATAVR19 and during wire manip-
ulation in the arch and valve implantation phases in either
TA or TF cases,20 but there was no correlation between
transcranial Doppler abnormalities and clinical neurologic
status or National Institutes of Health Stroke Score.rdiovascular Surgery c Volume 143, Number 4 839
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FIGURE 5. Hazard ratio of observed mortality after a neurologic event to expected mortality had the event not occurred. These hazard ratios represent the
distillation of observed and expected hazard functions for death with and without a neurologic event depicted in Figure E5. A, Hazard ratio for surgical open
aortic valve replacement (AVR) treatment arm over the first postoperative year, based on Figure E5, A and B. B, Hazard ratio for the transfemoral transcath-
eter aortic valve replacement (TF-TAVR) treatment arm over the first postoperative year, based on Figure E5, C and D. C, Hazard ratio for the transapical
transcatheter aortic valve replacement (TA-TAVR) treatment arm over the first postoperative year, based on Figure E5, E and F.
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ters across the arch,22 and temporary percutaneous embolic
deflectors23 are being investigated to determine whether in-
traprocedural cerebral embolism can be reduced. Concern
has been spawned by reports showing that postoperative
diffusion-weighted magnetic resonance imaging scans
show acute ischemic lesions diffusely scattered throughout
all territories of the brain in a majority of patients undergo-
ing either TA or TF-TAVR (68%-90%) and to a lesser de-
gree after AVR in lower surgical risk patients (8%-48%)
without high stroke rates,24-28 These abnormalities have
been termed ‘‘clinically silent,’’ but their potential impact
on neurocognitive and higher memory function remain
unclear.29-32 The total ischemic burden assessed by new
diffusion-weighted magnetic resonance imaging ischemic
lesions correlated with neurocognitive impairment, but the
findings were mixed.30-32 Sophisticated neuropsychologic
and cognitive testing in larger numbers of patients840 The Journal of Thoracic and Cardiovascular Surgundergoing TAVR and AVR correlated with long-term neu-
robehavioral outcome is necessary.17
One-half of neurologic events occurred late after the pro-
cedure, indicating how stroke-prone this elderly patient
population is. Measures aimed at reducing this risk may in-
clude intensified antiplatelet therapy before TAVR and/or
more aggressive anticoagulation after TAVR (possibly in-
cluding indefinite anticoagulation with warfarin or a direct
factor Xa or thrombin inhibitor16-18), although this remains
to be defined by prospective randomized clinical trials.17
Being assigned to the TA stratumwas the strongest determi-
nant of neurologic events late postoperatively, and the ad-
verse impact of this risk factor cut equally across both
TAVR and AVR treatment arms (Figure 3, C and D). This
late risk may not decline in the future unless more stringent
patient selection excludes persons with extensive general-
ized arteriosclerosis from being considered TAVR
candidates.ery c April 2012
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DThis study was conducted using large-caliber TAVR de-
livery systems predominantly in institutions without previ-
ous TAVR experience in old and sick patients. Therefore,
there is room for improvement, including technical refine-
ments, more astute patient selection, improved procedural
methods, and better anticoagulant and antiplatelet drug
therapy.16-18 Concerns about stroke during TAVR
remain,3,16-18,24-28 which will mandate more randomized
trials as only prospective controlled comparisons will
determine conclusively the risk/benefit ratio of TAVR
compared with open AVR.16,17 Future investigations will
also determine whether device improvements, for
example, smaller TAVR delivery systems, embolic
protection devices, better patient selection, and increased
operator experience, can reduce the incidence of
neurologic complications after TAVR.17,18 Until that
information becomes available, the 2011 American
College of Cardiology–Society of Thoracic Surgeons
recommendations for ‘‘rational dispersion’’ of TAVR
technology should be enforced,33 lest we repeat the health
care dilemma created by misuse and overuse of carotid ar-
tery stenting.34
Limitations
These implications cannot be extrapolated to individuals
other than the selected patients in the PARTNER cohort A
trial, which represents the highest decile of STS risk for iso-
lated AVR in the United States.2 Forty-seven (7%) patients
sustained 49 neurologic events, limiting the statistical infer-
ences that can be drawn. Only 29 major strokes occurred,
and the incidence was similar in the TAVR and AVR
arms. The analyses in the TA patient strata (both TAVR
and AVR) are limited by small sample and event sizes;
therefore, assumptions and clinical relevance inferred
from the TA patient analyses should be viewed as only pre-
liminary. Limitations inherent in assessment of neurologic
injury constitute weaknesses that will be rectified in the
PARTNER-2 trial. Incomplete information concerning anti-
coagulation and antiplatelet therapy was another limitation.
Neurologic events were possibly underestimated in AVR
patients owing to more prolonged sedation. Finally, patients
were followed up for only a minimum of 1 year, which man-
dates future long-term evaluation focused on valve durabil-
ity and the late occurrence of valve-related adverse events,
including neurologic complications.
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Dr John G. Byrne (Nashville, Tenn). Craig, this is a fantastic
paper, superbly delivered. First, the results of the PARTNER trial
show amazing results in both the traditional AVR as well as the
TAVR groups. This well-designed and executed study documented
the results using a first-generation large device in very elderly sick
patients in which all adverse events were adjudicated by a CEC.
We all congratulate you, Craig, and your coinvestigators on this
historic trial. I have 3 questions.
Do you believe, as I do, that TAVR is here to stay? That open
AVR, traditional AVR, for senile calcific AS is perhaps an endan-
gered species? That in the future, open AVR will be reserved for
cases of endocarditis, root disease, bicuspid disease and the very
young? Given the amount of investment in this technology, both
financial and intellectual, isn’t it just a matter of time that TAVR
will become the procedure of choice for most senile patients
with calcific AS? Once SAPIEN and eventually CoreValve are ap-
proved by the Food and Drug Administration, how can surgeons
remain involved? Will cardiologists own the TF approach and sur-
geons own the TA approach? How do we stay involved in the TF
approach to this?
Dr Miller. Thank you, John, for those kind comments, which
are very germane. The first question is related at preventing abuse
and inappropriate use of TAVR. How do we prevent a runaway
train, as what has happened in Germany where now 20%-25%
or more of all AVRs are done percutaneously? This is a question
that ultimately is going to be dictated by the payors, and we
must also be mindful of the fact we don’t even have medium-842 The Journal of Thoracic and Cardiovascular Surgterm valve durability data yet. TAVR is not going to be cost effec-
tive and affordable if these valves don’t outlast most of the patients
they are inserted in. Now, ‘‘a goodly amount of time’’ is rather
short for a 95-year-old who is otherwise inoperable; it is com-
pletely different if you have a patient under 70 who has a very
low surgical risk and should have a 15-20 year life expectancy.
So we have to learn a lot more about the durability of percutaneous
bioprosthetic valves before they are used in younger, healthier
patients.
The proof of the pudding will actually be at the payor level; they
are the only ones who can enforce how TEVAR is applied. Person-
ally I am disappointed by what has happened in Germany. Here in
the United States, we have no idea once one or both of these de-
vices are approved by the FDA, but it is essential that a truly func-
tional integrated heart valve team make sure that these
complementary technologies—TAVR and surgical AVR—are
used appropriately. The heart valve team and the payors must
draw and enforce both lower and upper boundaries based on
open surgical AVR risk and life expectancy to ensure reasonable
use of TAVR. The lower boundary separates out the younger
healthier patients who should undergo open AVR even if they de-
mand a catheter percutaneous valve. The upper boundary is the
line between utility and futility where we must learn to say
‘‘No.’’ Many elderly, very sick patients with critical AS are dying
of a host of other serious medical problems, which in the PART-
NERTrial we call ‘‘Cohort C.’’ They have extreme co-morbidities
that overwhelm the potential benefits of TAVR; indeed, successful
TAVR in these Cohort C patients may only prolong their suffering,
and certainly is financially irresponsible for society.
I don’t think open surgical AVR is an endangered species. There
are many patients with severe AS out there we as surgeons have
never seen who potentially can benefit from either TAVR or
AVR, as the PARTNER Trial Cohort A results illustrate. Remark-
ably, in the PARTNER Cohort B (inoperable) New England Jour-
nal of Medicine paper in October 2010, the TAVR patients gained
1.9 quality years of life and it only cost $US55,000 per QUALY,
substantially less than the cost of dialysis per QUALY. So in the
inoperable cohort TAVR is cost effective and provides meaningful
rehabilitation. In the younger high risk operable patients, we have
to work together in the heart valve team to determine whether
TAVR or AVR offers the best option for each individual patient.
I repeat that these are complementary treatment methods, not com-
petitive. On the other hand, the transapical TA-TAVR approach
may possibly be an endangered species since direct aortic access
TAVR is now being explored in Europe; an upper mini-sternotomy
or even high anterior right thoracotomy is better tolerated than
a low left small thoracotomy, and there is no LV injury from the
TA purse-string sutures. In the “TF first” PARTNER Cohort A
trial, however, being judged a non–TF-TAVR candidate confered
a higher risk patient to begin with, and an elevated risk of late neu-
rologic complications.
We need strict patient selection. The way we and the other
PARTNER sites have found this to work well is to make the entire
process truly a team effort: In the preoperative decision-making
phase, during the procedure (a surgeon and interventional cardiol-
ogist alternate being the primary operator in TF-TAVR cases at
Stanford), and taking care of the patients after TAVR. Marty
Leon will tell you himself that it is easier, more fun, and quickerery c April 2012
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groin. So if you share the experience amongst your team and learn
from each other, it actually can be synergistic. This takes mutual
respect and mutual trust. It is very refreshing at this stage of my
career to see cardiovascular surgeons and interventional cardiolo-
gists set aside our parochial self-interests and egos in order to work
together for the patient’s benefit.
Dr Byrne. Twomore questions: Your study showed that the risk
of stroke continues well after the procedure. What is the mecha-
nism of continued stroke? Is it thrombus formation on the prosthe-
sis or does calcium continue to break loose? We surgeons
meticulously remove calcium, and in TAVR the calcium is left be-
hind. Is it thrombus or calcium or both or just heavy atherosclerotic
burden?
Finally, given that the risk of stroke continues most markedly
between 1 month and 1 year after surgery, what approaches do
you and your coinvestigators recommend to mitigate stroke?
What is the role of dual antiplatelet therapy and cerebral protection
devices?
Dr Miller. John, those are also very good questions. Given we
used a large, second generation TAVR device and there was a steep
learning curve in most of the PARTNER centers (only 6 of the 26
sites had any prior TAVR experience), there is ample room for im-
provement in patient selection, procedural expertise, and postoper-
ative patient management.
Even though we can’t prove it, the early neurologic events
within the first few days were probably due to particulate cerebral
embolization. There are several cerebral embolic protection de-
flectors and filters being developed that cover the arch vessels
and may reduce this intraprocedural neurologic event risk. For
the neurologic complications occurring later on, we have to re-
member that there is a high background neurologic event inci-
dence in these very old, sick patients that none of us can
change. It is unknown whether dual antiplatelet therapy or per-
haps even warfarin or other anticoagulant drug administered
over the long-term might reduce the late neurologic event rate.
In the TAVR patients, there are many nooks and crannies remain-
ing around the native calcified cusps which possibly may lead to
stagnant flow with eventual thrombus formation around the SA-
PIEN valve. I don’t believe embolization of calcific debris from
the aortic cusps is a major factor late postoperatively. More likely
micro-thrombus or platelet aggregates are forming in some of
these blind niches around the percutaneous valve, which later
can embolize to the brain. This is an open question, and an impor-
tant one; there is hope for improvement in late risk of neurologic
events as the antiplatelet and antithrombotic treatment regimens
are refined.
Thank you.
Dr IrvingKron (Charlottesville, Va).Craig, that was a great dis-
cussion, and I know that your heart and soul has been in this study.
What amazedmewas, frankly, the terrific results both for openAVR
and the percutaneous device in the patients who had the TF
approach. Do you think our risk adjustment scores are accurate?
Dr Miller. That is a great question, Irv. We must recall that the
STS scores have never been completely validated out at this ex-
treme end of the spectrum. The PARTNER cohort A patientsThe Journal of Thoracic and Caconstitute the highest STS risk decile, or the upper 10th percentile
of STS risk, and there just haven’t been enough of them in the STS
database to be certain. To answer your question, based on our re-
sults from these 26 institutions, the STS expected operative risk
score would appear to overestimate the observed open surgical
AVR risk, but we do not have any certainty this would be true
US-wide, from which the STS database comes. What would be
the result of such a trial in a real world situation? We do not
know, but were pleasantly surprised by the low death rates and neu-
rologic event rates in both the AVR and the TAVR groups. This is
especially true since data monitoring was prospective, monitored,
audited, and an external Adverse Events Committee was looking
over our shoulder. We couldn’t hide anything in this study even
if we had tried.
Dr Thomas W. Rice (Cleveland, Ohio). I found the mortality
cost data interesting. If you receive an open AVR, the observed
risk of death approaches the expected. If you receive a TAVR,
the observed risk of death does not approach the expected. Do
you have any insight?
Dr Miller. I do not know, Tom, but I speculate that perhaps the
neurologic events in the AVR group may have been more severe
cerebral insults such that more patients died right away. Or perhaps
it reflects a difference in the philosophy and aggressiveness of the
treating local physicians. Most late neurologic events happened far
away from the PARTNER TAVR centers; if a patient after TAVR
sustained a serious stroke the primary care physicians and the fam-
ily may have been more nihilistic, saying something like, ‘‘well,
we gave it the best shot, but let’s not let Granny suffer anymore.’’
We just don’t know, but it is interesting.
Dr Hartzell V. Schaff (Rochester, Minn). Craig, I want to fol-
low up on a question that John Byrne asked you, which had to
dowith antiplatelet therapy. I believe that the transcatheter patients
were all treated with dual antiplatelet therapy for 6 months or
a year. Do you think that the lack of that in a surgical group had
anything to do with the difference in the late risk of stroke?
DrMiller. That is an excellent question, Hartzell. Dual antipla-
telet therapy was recommended postoperatively for all the TAVR
patients, but it was only a recommendation. How strictly it was ad-
hered to and for how long is poorly characterized. One large enroll-
ing center had very few early neurologic complications in the
TAVR patients; they used aggressive antiplatelet and anticoagulant
therapy. Antiplatelet therapy for the AVR patients was left to the
discretion of the local surgeons, but I suspect most of them also re-
ceived at least aspirin postoperatively. We need to unravel this di-
lemma more completely in the future, but most PARTNER
investigators today now pay more assiduous attention to the anti-
platelet and anticoagulation regimen, even including starting anti-
platelet drugs immediately before the TF procedures. Since there
was no difference in neurologic complication risk between the
TAVR and AVR subgroups during the late hazard phase, I do not
think antiplatelet therapy had any influence on neurologic event
risk. Recall that late postoperatively the strongest determinant of
neurologic events was being judged to be a ‘‘non-TF candidate,’’
which cut equally across the TAVR subgroup as well as the AVR
subgroup. This is a patient-related and disease-related risk factor,
which cannot be changed.rdiovascular Surgery c Volume 143, Number 4 843
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Detailed Methods
Study design, inclusion and exclusion criteria, study organi-
zation, study sites, principal investigators, follow-up, and
the SAPIEN transcatheter heart valve and delivery systems
have all been previously reported.E1,E2
Patient sample. The PARTNER trial enrolled only pa-
tients with severe AS and advanced cardiac symptoms
(New York Heart Association class  II). Patients were at
high-risk for conventional AVR based on coexisting condi-
tions predicting a risk of death by 30 days after operation of
15% or more. An STS mortality risk scoreE3 of 10% or
more was used as a floor for risk stratification, but the final
determination of operative risk was made by the local sur-
geons after dialogue on the biweekly PARTNER patient se-
lection conference call.
As previously reported,E1,E2 between May 11, 2007, and
August 28, 2009, from among the 3105 patients screened,
34% were ultimately randomized in PARTNER, with 699
(23%) being in the high operative risk cohort A limb.
Twenty-six sites participated, including 22 in the United
States and 3 in Canada; only 6 sites had previous TAVR ex-
perience. Because this study focuses on neurologic proce-
dural complications, only the 657 patients who underwent
assigned treatment (‘‘as treated,’’ or AT) were considered
further (42 patients excludedE2). An additional 2 patients
were excluded from analysis because they never received
their assigned treatment: one refused open AVR and sus-
tained a stroke during palliative BAV; the second had
a stroke before AVR, deteriorated clinically, and died.
Roll-in cases were also excluded, among which 4 patients
had neurologic events. Nine (2.6%) attempted TAVR cases
had to be aborted or converted, and multiple valves (‘‘valve-
in-valve’’) were acutely necessary for various exigencies in
7 TAVR patients.
Two cross-over patients experienced neurologic events:
one patient (TF stratum) who was randomized to TAVR
was converted from TF-TAVR to TA-TAVR on the table
when safe peripheral access could not be achieved and sus-
tained a major stroke on day 1. The other patient (TA stra-
tum, randomized to open AVR) underwent redo sternotomy
and attempted AVR but the procedure was aborted when
a totally calcified ascending aorta and arch were encoun-
tered. Six weeks later, this patient was allowed under Cana-
dian Compassionate Use provisions to cross over and
undergo TA-TAVR; he had a major stroke 11 months later.
These 2 patients were considered according to initial treat-
ment assigned in this analysis. A sensitivity analysis was
performed by rerunning the hazard function calculations af-
ter moving the second individual from the AVR group to the
TA-TAVR group: The coefficients in the model did not
change substantially, indicating this aberration did not af-
fect the conclusions.843.e1 The Journal of Thoracic and Cardiovascular SurStudy design, oversight, and data management. The
PARTNER trial study design and data management prac-
tices have been described previously.E1,E2 Patients were
randomized according to a computer-generated scheme,
blocked separately at each site and for each randomized
trial cohort. In the high-risk but operable cohort A, patients
were first categorized anatomically to either the TF-TAVR
or TA-TAVR stratum and then were randomized within their
assigned category to undergo either TAVR or AVR. For data
analysis of the ‘‘AT’’ patients, time 0 started with induction
of anesthesia. The trial was approved by institutional review
boards at each site. Written informed consents were ob-
tained for all patients.
The CONSORT patient flow diagram for the AT patients
analyzed is shown in Figure E1. Six hundred fifty-seven pa-
tients among the 699 individuals randomized in ITT re-
ceived designated treatment (‘‘as treated’’), 461 in the TF
and 196 in the TA stratum. Follow-up closing date was Sep-
tember 21, 2010, which corresponded to when every ITT
patient had been followed up for a minimum of 1 year
and 1 month. Four hundred eighty-four patients remained
at risk at 1 year and 124 patients at 2 years (111 were in
the TF stratum). It is important to note that only the overall
pooled TAVR versus AVR and the TF stratum (TF-TAVR
versus AVR) comparisons were adequately powered to de-
tect statistical noninferiority. No comparisons were ade-
quately powered to detect superiority. The data reflect the
clinical database as of May 6, 2011.
This study was designed by the sponsor and executive
committee, which included the 2 co-principal investigators,
3 interventional cardiologists, and 3 cardiovascular sur-
geons. The sponsor funded the trial and participated in se-
lection and management of the sites, collection of the
data, and data monitoring. The executive committee met
in person every 6 to 8 weeks to monitor all aspects of trial
conduct. The PARTNER Stroke Writing Group had unre-
stricted access to the data after the database was locked, per-
formed all data analyses, prepared all drafts of the
manuscript, and attests to the integrity of the trial and the
completeness and accuracy of the reported observations.
Neurologic end points. The Food and Drug Administra-
tion–approved PARTNER investigational device exemption
protocol for assessment of neurologic events was limited in
comprehensiveness.
Central nervous system (neurologic) events. A TIA was
defined as a focal neurologic event that was fully reversible
in less than 24 hours in the absence of any new imaging
findings of infarction or other primary medical cause
(eg, hypoglycemia or hypoxia). A stroke was defined as
a focal neurologic deficit lasting 24 hours or more or a
focal neurologic deficit lasting less than 24 hours with im-
aging findings of acute cerebral infarction or hemorrhage.
Stroke was further classified as ischemic, hemorrhagicgery c April 2012
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rhagic conversion. It was also determined if the event was
procedure or bioprosthetic device related after review of
available source documents and brain imaging reports (2
neurologic events were judged to be device-related in TF-
TAVR patients).Major and minor strokewere subsequently
distinguished through a CEC-adjudicated retrospective, un-
blinded analysis of neurologic events. A minor stroke was
defined as an event associated with a modified Rankin
Scale of 0 or 1 at 30 days or longer after the event or
a National Institutes of Health Stroke Scale score of 0.
This was determined by review of the source documenta-
tion surrounding the stroke, including but not limited to
progress notes, consult notes, discharge summaries, and
follow-up clinic notes. If National Institutes of Health
Stroke Scale information was available, this was incorpo-
rated into the adjudication. A major stroke was defined as
a modified Rankin Scale score of 2 or more at 30 days or
longer after the event.
The CEC could not judge the severity of the stroke in 6
cases and did not comment on severity of stroke when ade-
quate source materials in their opinion were not available;
these cases were examined by the PARTNER Trial Execu-
tive Committee and a collective decision made regarding
severity of stroke. If the severity of neurologic injury was
unclear, the default decision was to label the event a major
stroke to be conservative. Two investigators (D.C.M. and
M.J.M.) reviewed the CEC summaries and all available
source documents for the 47 patients who sustained a neuro-
logic event to corroborate the CEC and executive commit-
tee’s decisions. No irreconcilable discordance with the
CEC adjudications was encountered.
Data Analysis and Detailed Statistical Methods
Categorical variables were compared using Fisher’s ex-
act test. Continuous variables are presented as means (1
standard deviation) and compared using the Student t test.
When the data were markedly skewed, continuous variables
are also presented as median with interquartile range. Data
analysis was based on the ‘‘as treated’’ or AT principle.
Time-to-event analyses were based on all available
follow-up data that extended beyond 2 years. All analyses
were performed using SAS statistical software (SAS ver-
sion 9.2; SAS Institutes, Inc, Cary, NC). Both nonparamet-
ric (actuarial) and parametric estimates of neurologic event
occurrence are presented with asymmetric 68% confidence
intervals, comparable to1 standard error. We also present
nomograms of the multivariable analyses (risk-adjusted so-
lutions of the multivariable equation) for illustration. To en-
hance the certainty of the estimates, the ‘‘Berkson rule’’ of
drawing the actuarial curves out until about 10% of cases
remained alive without the event was employed; thereafter,
what is known as the ‘‘completion effect’’ kicks in (the
larger the original sample size the longer it takes for theThe Journal of Thoracic and Cardcompletion effect to take hold, so for very large studies
one can extend the actuarial curves much longer out). In
general, the parametric method used in this manuscript is
less sensitive to completion effects than are nonparametric
actuarial (eg, Kaplan-Meier) methods. The parametric
models were carried out to 2 years except for the TA stra-
tum, where limited follow-up only made 1-year estimates
meaningful (Figure E1).
End points. The main focus of this analysis was on time-
related central neurologic events, 49 of which occurred in
47 patients. Although we explored repeated events, the
analyses were time to the first neurologic event. As a sec-
ondary analysis, we estimated risk of major stroke, but
the smaller numbers (n ¼ 29) precluded meaningful statis-
tical analyses; furthermore, our ability to determine accu-
rately the severity of the neurologic damage was limited
in the PARTNER-I trial. No reliable information was avail-
able regarding residual permanent disability after a stroke.
We then placed these neurologic events into the context of
the ongoing competing risk of death before a neurologic
event occurs. Finally, we examined death after a neurologic
event.
Missing values. A number of variables examined in multi-
variable analyses had missing values. We used 5-fold mul-
tiple imputationE4 using a Markov Chain Monte Carlo
technique to impute missing values (SAS PROC MI). In
multivariable modeling, for each imputed complete data
set, we have estimated the regression coefficients and their
variance–covariance matrix. Then following Rubin,E4 we
combined estimates from the 5 models (SAS PROC MIA-
NALYZE) to yield final regression coefficient estimates,
the variance–covariance matrix, and P values.
Time-varying instantaneous risk (hazard function) and
occurrence of neurologic events. Nonparametric analyses
of neurologic events overall and in each of the 2 treatment
arms revealed an early high-risk periprocedural phase fol-
lowed by a lower persistent occurrence of events for as
long as the patients had been monitored. Two analyses
were performed to determine occurrence of neurologic
events as a function of time, define hazard functions, and
identify incremental risk factors. The first was freedom
from a neurologic event (47 events in 47 patients, ordinary
time-to-event analysis), which was assessed nonparametri-
cally using the Kaplan-Meier estimator and parametrically
using a multiphase hazard model.E5 The parametric model
was used to resolve a number of phases of instantaneous
risk of the event (hazard function) and to estimate shaping
parameters. In most cases, 2 hazard phases were resolved;
the sum of these is the overall hazard. The second approach
included all neurologic events, 49 in 47 patients, treated as
repeated outcomes. Nelson’sE6,E7 cumulative event
function was used to obtain nonparametric estimates. The
cumulative number of events per patient was also
estimated by multiphase hazard function methodology toiovascular Surgery c Volume 143, Number 4 843.e2
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This manuscript focuses on the first approach: the initial
neurologic event for each patient.
Preprocedural factors associated with early and late
neurologic events. Because 2 distinct phases of risk were
identified, it was likely that there were different risk factors
or mechanisms responsible for each phase. One caveat is
that with only 47 patients experiencing events (effective
sample size), the ability to identify these factors was lim-
ited. We therefore performed a sequential analysis. The first
only considered preprocedural factors common to both
treatments, TAVR and AVR. No interaction terms were con-
sidered at this stage (factors that may be more strongly re-
lated to risk in 1 group than the other). The method to
search for possible interacting factors that modulate risk
in 1 treatment arm more or less than in the other arm is de-
scribed below. In the multivariable analysis, factors modu-
lating both hazard phases were considered simultaneously.
Early risk factors were those found to increase the area be-
neath the early peaking hazard phase, and late risk factors
increased the level of underlying late constant hazard.
Within each hazard phase, we assumed proportional haz-
ards, but because the 2 hazard phases are operative across
all time, this produces overall a nonproportional hazard
model. Such a model is particularly appropriate for strongly
time-varying hazard, as is evident for neurologic events in
this study.
Preoperative variables considered in the analysis are
listed in Table E6. Variable selection, with a P value
criterion for retention of variables in the model of .07 be-
cause of the small number of events, used a computer-
intensive machine learning ‘‘bagging’’ method (bootstrap
aggregation).E8,E9 This was a 4-step process. First, a pa-
tient was randomly selected from the original data set to
begin a new data set. The original data set continued to
be sampled until the new data set was 100% the size of
the original. In general, about two-thirds of patients are
unique using such a sampling-with-replacement method,
and about one third are duplicate patients. Second, risk
factors were identified using automated forward stepwise
selection. Third, results of the variable selection were
stored. These 3 steps were repeated 500 times. Finally,
the frequency of occurrence of variables found in these
analyses was ascertained and indicated the reliability of
each variable (aggregation step). It is generally thought
that variables with bootstrap reliability of 50% or greater
should be retained in the model. As will be noted, 1 factor
with a P value< .1 was retained in addition. No other fac-
tor was found to be close in reliability. An interpretation of
reliability from such an analysis is that it represents the
probability that the P value is less than .07.
Intraprocedure-specific factors associated with early
and late neurologic events. In addition to the general pre-
operative factors, intraprocedural risk factors specific to843.e3 The Journal of Thoracic and Cardiovascular Surgeach of the 2 procedures might influence stroke risk
(Table E7). Each procedure group was analyzed separately
to allow clues to emerge linking possible preoperative fac-
tors that are specific to each treatment arm. Generally, sep-
arate analyses such as these make it easier to detect possible
interaction terms than forming the product of procedure
with each variable in the analysis. In the TAVR arm, the
only intraprocedural variable that was statistically signifi-
cant was TA stratum, which increased risk during the late
phase. This analysis strongly suggested that smaller native
aortic valve area or higher mean transvalvular gradient
might possibly be additional preprocedural risk factors. In
the AVR arm, no procedural variable was statistically sig-
nificant. Aortic valve size was not identified as a risk factor
for neurologic events after AVR.
Variables specific to the procedure itself, as well as pre-
procedural variables, were analyzed using the same ma-
chine learning methodology previously described for
preprocedural factors. Some variables could not be ana-
lyzed reliably, including valve embolism (TAVR group) be-
cause of too few events associated with this uncommon
occurrence.
Pre-procedural risk factors for neurologic events spe-
cific to the treatment procedures. Analysis of predictors
of neurologic events in each procedure arm suggested there
may be preprocedural risk factors, particularly related to na-
tive aortic valve size, that may be specific for each of the
treatment arms— so-called interaction terms in analysis
of the pooled procedures. On the basis of the separate anal-
yses of each treatment arm, we formed interaction terms
with treatment to determine the following: (1) if there are
risk factors for 1 and not the other procedure and (2) if
strength of risk factors differed significantly between the
arms. We confined our search for interaction terms to those
related to the 2 procedures, not interaction among other risk
factors, even though there is controversy among statisti-
cians about how to express interaction terms such as this
for continuous variables. We show that native valve size is
only relevant to the TAVR arm, meaning that the factor is
not relevant to the AVR arm (coefficient is 0). This is similar
to how other variables that were not statistically significant
were managed.
Further refinement of the model of risk factors for
neurologic event and taking into account patient size.
Examining variables reflecting patient size might poten-
tially be particularly relevant to understanding the native
aortic valve area risk factor in the TAVR group. In addition,
the ratio of annulus dimension to prosthesis dimension (rec-
ognizing that this measurement differs among heart valve
devices) was examined. Indexed aortic valve area (AVAI,
valve area divided by body surface area [cm2/m2]) and in-
dexed and normalized bioprosthesis size were forced into
the model along with interactions with procedure (AVR
vs TAVR). AVAI within the TAVR group was not onlyery c April 2012
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logic events than unindexed AVA, the unindexed AVAvari-
able then fell out of the model (P > .3, Table 2).
Bioprosthesis size (absolute, indexed, and normalized to an-
nulus) was not found to be associated with increased risk of
neurologic events in either hazard phase, with or without in-
teractions. Note that in Table 2 the variable TAVR in the
early hazard phase when interactions are considered be-
comes an offset to the intercept term in the model.
Analysis of major stroke. We analyzed all neurologic
events out of necessity owing to the relatively small num-
ber of events, but for completeness sake we attempted to
depict the incidence and hazard of major stroke despite
major constraints that limited our ability to discriminate
precisely the severity of neurologic damage sustained. Of
the 31 neurologic events after TAVR, 18 were adjudicated
to be major strokes, as were 11 of the 16 events after AVR.
Of note, a number of neurologic events could not be clas-
sified and arbitrary conservative default judgments were
made (vide supra). We used the same multiphase hazard
function methodology to estimate the hazard function for
major strokes as used for all neurologic events (see
Figure E3, A to C).
Competing risks of death and neurologic event. Actuar-
ial and parametric estimates of the rate of neurologic
event rates describe what happened for the entire patient
sample being investigated; as time passes patients die (es-
pecially in this very old and sick patient cohort) and the
question emerges: ‘‘What is the likelihood of experiencing
a neurologic event given this strong competing risk of
death?’’ Put more simply, what individual patients want
to know is: ‘‘What are the odds if I am still alive I will
be free from a neurologic event?’’ We explored this im-
portant and commonly asked question using competing
hazard analysis where the following 2 mutually exclusive
outcomes were considered as competing events: death be-
fore experiencing a neurologic event and sustaining a neu-
rologic event.
A common interval was defined for analysis as the earli-
est of either death or neurologic event. Patients then transi-
tion from being alive without a neurologic event into 2
mutually exclusive states: neurologic event or death before
such an event. Freedom from each event was estimated by
the nonparametric product limit method.E10 Variances of
the estimates were based on Greenwood formula.E10 Be-
cause of the difference in neurologic event risk according
to TF or TA stratum, the TAVR group was analyzed accord-
ing to ‘‘as stratified’’ approach, recognizing that the ap-
proach is indicative of more generalized atherosclerotic
burden and not the TF or TA TAVR procedure per se. The
results are illustrated for all 4 subsets of patients individu-
ally in Figure E4, A to D, and summarized in Figure 4 in
the main manuscript. An assumption in competing risks
analysis is that censoring at times of transition into eachThe Journal of Thoracic and Carstate is ‘‘noninformative’’ (eg, timing of a neurologic event
is not informative of time of death). This is an artificial as-
sumption, and methods for managing ‘‘informative censor-
ing’’ exist, but this is an area of statistical research, not of
statistical practice.
‘‘Mortality cost’’ of a neurologic event. Neurologic
events carry not only a morbidity cost to the patient, but
a mortality cost. Survival after a neurologic event was esti-
mated nonparametrically by the Kaplan-Meier estimator
and parametrically using a multiphase hazard model.E4
Time 0 was the time of the first neurologic event in the 47
patients. Mere depiction of survival after a neurologic event
does not, however, answer the question of the mortality cost
of such an event. For this, we need to estimate survival had
the event not occurred. It is not correct to ask what survival
was in patients who never experienced a neurologic event,
because this assumes that ahead of time one knows who
will experience such an event and who will not. Thus, we
first estimated mortality before a neurologic event for all
trial patients from the time of the procedure, stratified by
AVR and within TAVR by TF and TA approaches. This is
identical to the competing risks approach described above,
where the death curve is ‘‘death before neurologic event,’’
which we parametrically estimated using the multiphase
hazard model. The next step was to use the parametric equa-
tion for survival before a neurologic event to generate a sur-
vival curve for each patient experiencing a neurologic event
after the time the event occurred. This is known as condi-
tional survival, which starts at 100% at the time of a neuro-
logic event. We then computed the average of those 47
curves, which is the expected survival beyond the time of
neurologic event had it never occurred. The third step is
to compare the actual survival curve from time of neuro-
logic event to the expected survival curve had the event
not occurred (Figure E5, A to F). Although the comparative
results can be portrayed several different ways, difference in
survival across time, hazard ratio across time, or decrement
in lifetime (the area between the curves), in this manuscript,
we present the hazard ratio across time (Figure 5, A to C). A
hazard ratio of 1.0 means observed and expected risk at that
instant of time is identical.
Factors distinguishing TA-TAVR candidates from TF-
TAVRcandidates. Non–TF-TAVR candidates had a higher
risk of neurologic events than did TF candidates in the late
constant hazard phase. We investigated preprocedural
patient-related and disease-related factors that distin-
guished TA from TF stratum candidates. Multivariable lo-
gistic regression was used that employed the patient
factors from Table E6. Bagging was used for variable
selection. Table E2 verifies the clinical impression that
arteriosclerotic vascular disease (equally peripheral and ce-
rebrovascular disease) strongly characterized TA candi-
dates. In addition, women were more likely to fit this
profile as were those who had previous CABG.diovascular Surgery c Volume 143, Number 4 843.e4
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likelihood of being a TA candidate. As anticipated, more re-
cent time frame included more TA candidates owing to trial
design (the TA limb enrollment started 1 year after the TF
arm) and is reflected in shorter follow-up of these patients.
A graphic depiction of this analysis is shown in Figure E2.
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FIGURE E2. Patient characteristics segregating the transapical (TA) stra-
tum from the transfemoral (TF) stratum, which was carried out before ran-
domization into the transcatheter aortic valve replacement (TAVR) or
surgical aortic valve replacement (AVR) treatment limbs. PVD, Peripheral
vascular disease; CEA, carotid endarterectomy or stenting; CABG, coro-
nary artery bypass grafting.
Miller et al Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery c Volume 143, Number 4 843.e6
A
C
D
FIGUREE3. Major stroke after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (AVR). A, Occurrence of major stroke.
Each symbol represents an event; vertical bars are confidence limits equivalent to  1 standard error, and solid lines enclosed within dashed confidence
bands indicating 1 standard error represent parametric estimates. Numbers of patients at risk are denoted below the horizontal axis at 6-month intervals.
The red curve and open squares depict the TAVR pooled (TA and TF strata) arm and the blue curve and open circles are for the surgical AVR pooled arm.
Numberswithin the plot are point estimates at 12 and 24 months. B, Instantaneous hazard of major stroke. Solid lines represent parametric estimates and are
enclosed within asymmetric confidence bands equivalent to  1 standard error. The red curve is for TAVR; the blue curve is for AVR. C, Instantaneous
hazard of major stroke after TAVR or AVR. The depiction is identical to that in Figure E3, B, except that the vertical axis is expanded and the horizontal
axis has been stretched to 24 months to depict later hazard.
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FIGURE E4. Competing risks of death or neurologic event after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement
(AVR). At each time point, ‘‘alive without neurologic event’’ (or ‘‘event-free survival’’), ‘‘death before neurologic event’’, and ‘‘neurologic event’’ add
to 100%. Each symbol represents an event; vertical bars are confidence limits equivalent to 1 standard error, and solid lines enclosed within dashed con-
fidence bands indicating  1 standard error represent parametric estimates. A, Competing risks after TAVR for patients assigned to the transfemoral (TF)
stratum, that is, the TF-TAVR subgroup. B, Competing risks after TAVR for patients assigned to the transapical (TA) stratum, that is, the TA-TAVR subgroup.
C, Competing risks after AVR for patients assigned to the transfemoral (TF) stratum. D, Competing risks after AVR for patients assigned to the transapical
(TA) stratum. Note that follow-up has been truncated at 1.9 years when less than 10% of patients in this subgroup remained at risk.
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FIGURE E5. Mortality after a neurologic event following transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (AVR).
A, Mortality after a neurologic event in the AVR treatment arm over the first postoperative year. Each symbol represents a death; vertical bars are confidence
limits equivalent to 1 standard error, and solid lines enclosed within dashed confidence bands indicating 1 standard error represent parametric estimates.
The blue curve is observedmortality and the black curve represents an estimate of mortality had a neurologic event not occurred. B, Early hazard function for
death out to 3 months after a neurologic event for the AVR treatment arm. The blue curve is observed hazard and the black curve is hazard function for
mortality as if a neurologic event had not occurred. C, Mortality after a neurologic event in the TF-TAVR treatment arm over the first postoperative
year. The depiction is as in Figure E5, A. The red curve is observed mortality and the black curve enclosed in a dashed confidence band equivalent to 1
standard error represents an estimate of mortality had a neurologic event not occurred. D, Early hazard function for death out to 3 months for mortality after
a neurologic event following TF-TAVR. The red curve is observed hazard and the black curve is hazard function for mortality as if a neurologic event had not
occurred. E, Mortality after a neurologic event in the TA-TAVR treatment arm over the first postoperative year. The depiction is as in Figure E5, A. The green
curve is observed mortality and the black curve enclosed in a dashed confidence band equivalent to 1 standard error represents an estimate of mortality had
a neurologic event not occurred. F, Early hazard function for death out to 3 months after a neurologic event in the TA-TAVR treatment arm. The green curve
is observed hazard and the black curve is hazard function for mortality as if a neurologic event had not occurred.
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TABLE E1. Baseline characteristics of ‘‘as treated’’ (AT) patients assigned to TF or TA stratum
Variable TA (n ¼ 196) TF (n ¼ 461) P value
Age (y) 83.2  6.3 84.3  6.7 .04
Female gender 88/196 (44.9%) 192/461 (41.6%) .49
STS risk score 11.9  3.6 11.7  3.3 .53
Logistic EuroSCORE 29.9  15.5 29.0  16.0 .54
NYHA class III or IV 184/196 (93.9%) 437/461 (94.8%) .71
Body surface area (m2) 1.8  0.3 1.8  0.2 .97
Carotid endarterectomy/stent 40/192 (20.8%) 36/452 (8.0%) <.01
Peripheral arterial bypass graft 11/191 (5.8%) 6/455 (1.3%) <.01
Other arterial stent or PTA 21/191 (11.0%) 15/455 (3.3%) <.01
Stroke or TIA within last 6-12 mo 7/191 (3.7%) 12/458 (2.6%) .45
Previous CABG 102/194 (52.6%) 182/457 (39.8%) <.01
No. of previous CABGs 82/102 (80.4%) 155/184 (84.2%) .71
Coronary artery disease 153/194 (78.9%) 346/459 (75.4%) .37
Previous Q wave or non-Q wave MI 62/192 (32.3%) 120/454 (26.4%) .15
Previous PCI 72/187 (38.5%) 144/455 (31.6%) .10
Cerebrovascular disease 66/177 (37.3%) 108/428 (25.2%) <.01
Peripheral vascular disease 120/192 (62.5%) 159/455 (34.9%) <.01
COPD—any 87/136 (64.0%) 200/313 (63.9%) 1.00
Oxygen-dependent pulmonary disease 19/138 (13.8%) 53/319 (16.6%) .49
Previous pacemaker implant 38/194 (19.6%) 101/458 (22.1%) .53
Pulmonary hypertension 93/194 (47.9%) 229/420 (54.5%) .14
Creatinine 1.5  2.0 1.6  3.2 .45
Atrial fibrillation (ECG Core Lab) 46/168 (27.4%) 99/408 (24.3%) .46
CHADS2 stroke risk score 2.5  0.7 2.4  0.7 .36
Deleterious effects of chest-wall irradiation 2/196 (1.0%) 3/461 (0.7%) .64
Liver disease 2/192 (1.0%) 13/458 (2.8%) .25
Coronary artery stenosis>50% 124/194 (63.9%) 263/463 (56.8%) .07
Aortic valve annulus diameter (cm) 2.0  0.2 2.0  0.2 .99
Aortic valve mean gradient (mmHg) 41.1  13.4 43.9  14.8 .03
Aortic valve area (cm2) 0.7  0.2 0.6  0.2 .32
Aortic valve area index (cm2/m2) 0.4  0.1 0.4  0.1 .47
LV ejection fraction (%) 53.5  11.5 52.9  13.6 .56
All continuous variables expressed as mean  1 standard deviation. TF, Transfemoral; TA, transapical; STS, Society of Thoracic Surgeons; NYHA, New York Heat association;
PTA, percutaneous transluminal angioplasty; TIA, transient ischemic attack; CABG, coronary artery bypass grafting;MI, myocardial infarction; PCI, percutaneous coronary in-
tervention; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; CHADS2, Congestive heart failure, Hypertension, Age, Diabetes mellitus, prior Stroke or
transient ischemic attack; LV, left ventricular.
Miller et al Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery c Volume 143, Number 4 843.e10
A
C
D
TABLE E3. Baseline characteristics of patient ‘‘as treated’’ (AT) population according to randomized treatment arm (TAVR vs AVR)
Variable AVR (n ¼ 313) TAVR (n ¼ 344) P value
Age (y) 84.4  6.3 83.6  6.8 .12
Female gender 134/313 (42.8%) 146/344 (42.4%) .94
STS risk score 11.7  3.4 11.8  3.3 .65
Logistic EuroSCORE 29.2  15.2 29.4  16.5 .90
NYHA class III or IV 297/313 (94.9%) 324/344 (94.2%) .73
Body surface area (m2) 1.8  0.2 1.8  0.3 .89
Carotid endarterectomy/stent 29/307 (9.4%) 47/337 (13.9%) .09
Peripheral arterial bypass graft 7/306 (2.3%) 10/340 (2.9%) .63
Other arterial stent or PTA 15/307 (4.9%) 21/339 (6.2%) .50
Stroke or TIA within 6-12 mo 9/309 (2.9%) 10/340 (2.9%) 1.00
Previous CABG 139/310 (44.8%) 145/341 (42.5%) .58
No. of previous CABGs 112/139 (80.6%) 125/147 (85.0%) .46
Coronary artery disease 241/310 (77.7%) 258/343 (75.2%) .46
Previous Q wave or non-Q wave MI 90/307 (29.3%) 92/339 (27.1%) .54
Previous PCI 101/305 (33.1%) 115/337 (34.1%) .80
Cerebrovascular disease 79/285 (27.7%) 95/320 (29.7%) .65
Peripheral vascular disease 132/307 (43.0%) 147/340 (43.2%) 1.00
COPD 138/214 (64.5%) 149/235 (63.4%) .84
Oxygen-dependent pulmonary disease 34/220 (15.5%) 38/237 (16.0%) .90
Previous pacemaker implant 70/311 (22.5%) 69/341 (20.2%) .50
Pulmonary hypertension 150/293 (51.2%) 172/321 (53.6%) .57
Creatinine 1.6  3.3 1.5  2.5 .71
Atrial fibrillation (ECG Core Lab) 66/269 (24.5%) 79/307 (25.7%) .77
CHADS2 stroke risk score 2.5  0.7 2.4  0.7 .31
Deleterious effects of chest wall irradiation 2/313 (0.6%) 3/344 (0.9%) 1.00
Liver disease 8/310 (2.6%) 7/340 (2.1%) .80
Coronary artery stenosis>50% 184/313 (58.8%) 203/344 (59.0%) 1.00
Aortic valve annulus diameter (cm) 2.0  0.2 2.0  0.2 .93
Aortic valve mean gradient (mm Hg) 43.5  14.3 42.7  14.5 .51
Aortic valve area (cm2) 0.6  0.2 0.7  0.2 .32
Aortic valve area index (cm2/m2) 0.4  0.1 0.4  0.1 .31
LV ejection fraction (%) 53.6  12.5 52.6  13.5 .35
All continuous variables expressed as mean  1 standard deviation. TF, Transfemoral; TA, transapical; STS, Society of Thoracic Surgeons; NYHA, New York Heat association;
PTA, percutaneous transluminal angioplasty; TIA, transient ischemic attack; CABG, coronary artery bypass grafting;MI, myocardial infarction; PCI, percutaneous coronary in-
tervention; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; CHADS2, Congestive heart failure, Hypertension, Age, Diabetes mellitus, prior Stroke or
transient ischemic attack; LV, left ventricular.
TABLE E2. Parsimonious logistic regression model to identify
patient-related and disease-related factors that were associated with
a higher likelihood of being deemed to be a ‘‘non-TF candidate’’ for
TAVR
Risk factor Coefficient ± SD P value R (%)
History of peripheral vascular
disease
0.84  0.19 <.0001 98
Carotid endarterectomy/stent 0.86  0.28 .002 78
Female 0.72  0.21 .0008 82
History of CABG 0.51  0.21 .02 61
Lower AV mean gradient 0.020  0.0072 .006 58
Recent date of surgery/implant 1.4  0.22 <.0001 100
R (%), Bagging reliability; CABG, coronary artery bypass grafting; AV, aortic valve;
SD, standard deviation. C-statistic ¼ 0.75. Note: The ‘‘recent date of surgery/im-
plant’’ term is explained by the fact that the transapical (TA) limb of the transcatheter
aortic valve replacement (TAVR) treatment arm did not start until 1 year after the
transfemoral (TF) limb. Also, centers were not permitted to commence TA-TAVR
cases until after they had gained a substantial experience with TF-TAVR cases.
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TABLE E4. Selected baseline characteristics for the 4 subgroups of AT patients categorized by assigned stratum (TF vs TA) and randomized
treatment arm (TAVR vs AVR)
Variable
TA stratum TF stratum
AVR (n ¼ 92) TA-TAVR (n ¼ 104) AVR (n ¼ 221) TF-TAVR (n ¼ 240)
Age (y) ( 1 SD) 83.4  5.5 82.9  7.0 84.8  6.6 83.9  6.8
STS risk score 12.1  3.5 11.7  3.6 11.5  3.3 11.9  3.2
Logistic EuroSCORE 29.9  15.1 29.9  16.0 28.9  15.2 29.1  16.7
NYHA class III or IV 96% 92% 95% 95%
Carotid endarterectomy/stent 17% 24% 6% 10%
Stroke or TIA within last 6-12 mo 7% 1% 1% 4%
Previous CABG 56% 50% 40% 40%
Coronary artery disease 84% 75% 75% 75%
Previous Q wave or non-Q wave MI 38% 28% 26% 27%
Cerebrovascular disease 31% 43% 26% 24%
Peripheral vascular disease 62% 63% 35% 35%
COPD 64% 64% 65% 63%
Pulmonary hypertension 42% 53% 55% 54%
Atrial fibrillation 21% 32% 26% 23%
Mean aortic valve gradient (mm Hg) 40.5  12.9 41.7  13.9 44.7  14.8 43.1  14.8
Aortic valve area (cm2) 0.7  0.2 0.7  0.2 0.6  0.2 0.7  0.2
Aortic valve area index (cm2/m2) 0.4  0.1 0.4  0.1 0.3  0.1 0.4  0.1
LV ejection fraction (%) 53.5  10.9 53.6  12.2 53.6  13.1 52.2  14.0
All continuous variables expressed as mean  1 standard deviation. TF, Transfemoral; TA, transapical; SD, standard deviation; STS, Society of Thoracic Surgeons; NYHA, New
York Heat association; TIA, transient ischemic attack; CABG, coronary artery bypass grafting;MI,myocardial infarction; COPD, chronic obstructive pulmonary disease; LV, left
ventricular.
TABLE E5. Procedural details of patient population (AT) according to randomized treatment arm (TAVR vs AVR)
TAVR (n ¼ 344) AVR (n ¼ 313)
Days to implant 10.8  13.8 Days to implant 15.6  19.7
Anesthesia duration (min) 236.3  96.4 Anesthesia duration (min) 330.3  104.4
Total procedure time (min) 133.1  88.6 Total procedure time (min) 230.0  45.5
Fluoroscopy time (min) 31.3  75.7 Total crossclamp time (min) 73.5  28.7
Aborted procedure, no. (%) 7 (2.0%) Pump time (min) 104.9  41.4
Converted procedure, no. (%) 9 (2.6%) Aborted procedure, no. (%) 0 (0%)
Due to valve embolization 5 Converted procedure, no. (%) 1 (0.3%)
Due to annulus size on TEE 3 Due to extremely calcified aorta 1
Due to large sigmoid septum 1
Reoperation for bleeding, no. (%) 2 (0.6%) Reoperation for bleeding, no. (%) 12 (3.4%)
Intraprocedural death, no. (%) 3 (0.9%) Intraprocedural death, no. (%) 1 (0.3%)
Vascular access infection, no. (%) 7 (2.0%) Sternal wound infection, no. (%) 7 (2.0%)
Valve embolization (not reported as
conversion or valve-in-valve), no. (%)
2 (0.6%)
Multiple valve ( 2 implanted), no. (%) 7 (2.0%)
Due to valve embolization 2
Due to residual aortic regurgitation 5
Coronary obstruction, no. (%) 0 (0.0%)
Aortic perforation-no. (%) 0 (0.0%) Aortic perforation, no. (%) 1 (0.3%)
Aortic dissection, no. (%) 3 (0.9%) Aortic dissection, no. (%) 2 (0.6%)
Average ICU stay (d) 5.9 median ¼ 3.0 (IQR 2, 6) Average ICU stay (d) 8.4 median ¼ 5.0 (IQR 3, 8)
Average index hospital stay (d) 11.7 median ¼ 8 (IQR 5, 14) Average index hospital stay (d) 16.7 median ¼ 12 (IQR 8, 20)
AT,As treated; TAVR, transcatheter aortic valve replacement;AVR, aortic valve replacement; TEE, transesophageal echocardiography; ICU, intensive care unit; IQR, inter-quartile
range.
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TABLE E6. Preprocedural variables considered in analyses
Demographics
Age at screening
Gender
Clinical Status
NYHA class
Logistic EuroSCORE
STS risk score
CHADS2 stroke risk score
Aortic valve pathology
Aortic valve annular diameter
Aortic valve area
Aortic valve area index
Aortic valve mean gradient
Endocarditis
Cardiac comorbidity
Moderate or severe mitral regurgitation
Coronary artery stenosis>50%?
Coronary artery disease
No, of previous CABGs
Prior CABG
Prior PCI
Previous Q wave or non-Q wave MI
LV ejection fraction
Atrial fibrillation (ECG Core Lab)
History of atrial fibrillation or other arrhythmias
Pacemaker implant
Cardiovascular comorbidity
Cerebrovascular disease
Stroke or TIAwithin last 6-12 mo
Carotid endarterectomy/stent
No. of prior aortic valvuloplasties
Porcelain aorta
Aortic dissection
Peripheral vascular disease
Peripheral bypass graft
Other arterial stent or PTA
Pulmonary hypertension
Deleterious effects of chest wall irradiation
Transapical vs transfemoral assigned stratum
Noncardiac comorbidity
Liver disease
Creatinine
COPD
Oxygen-dependent COPD
Treatment variables
AT trial arm (computed)
AT implant approach
Implant procedure date
NYHA, New York Heat Association; STS, Society of Thoracic surgeons; CHADS2,
Congestive heart failure, Hypertension, Age, Diabetes mellitus, prior Stroke or tran-
sient ischemic attack; CABG, coronary artery bypass grafting; PCI, percutaneous
coronary intervention; MI, myocardial infarction; LV, left ventricular; ECG, electro-
cardiogram; TIA, transient ischemic attack; PTA, percutaneous transluminal angio-
plasty; COPD, chronic obstructive pulmonary disease.
TABLE E7. Procedural variables considered in analyses
TAVR-specific variables
Implant approach (as treated)
Fluoroscopy total time (min)
Aortic perforation
Second THV valve implanted
Device embolization
Conversion to open cardiac surgery
Surgical AVR-specific variables
Total aortic crossclamp time
Anesthesia duration
Pump time
General procedure variables
Valve size
Derived device size
TAVR, Transcatheter aortic valve replacement; THV, transcatheter heart valve; AVR,
aortic valve replacement.
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